The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM D

Notice of Exempt Offering of Securities

OMB APPROVAL

OMB 3235-Number: 0076

Estimated average

burden

hours per response:

4.00

1. Issuer's Identity

CIK (Filer ID Number)

Previous
Names

None

Entity Type

0001400118 3-V Biosciences, Inc. X Corporation

Name of Issuer Limited Partnership

Sagimet Biosciences Inc.

Limited Liability Company

Jurisdiction of
Incorporation/OrganizationGeneral PartnershipDELAWAREBusiness TrustOther (Specify)

Year of Incorporation/Organization

X Over Five Years Ago

Within Last Five Years (Specify Year)

Yet to Be Formed

2. Principal Place of Business and Contact Information

Name of Issuer

Sagimet Biosciences Inc.

Street Address 1 Street Address 2

155 BOVET RD., SUITE 303

City State/Province/Country ZIP/PostalCode Phone Number of Issuer

SAN MATEO CALIFORNIA 94402 (650) 561-8600

3. Related Persons

Last Name First Name Middle Name

Kemble George

Street Address 1 Street Address 2

Sagimet Biosciences Inc. 155 Bovet Rd., Unit 303

City State/Province/Country ZIP/PostalCode

San Mateo CALIFORNIA 94402

Relationship: X Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

Hom Dennis

Street Address 1 Street Address 2

Sagimet Biosciences Inc. 155 Bovet Rd., Unit 303

City State/Province/Country ZIP/PostalCode

San Mateo CALIFORNIA 94402

Relationship: X Executive Officer Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

Parsey Merdad

Street Address 1 Street Address 2

Sagimet Biosciences Inc. 155 Bovet Rd., Unit 303

City State/Province/Country ZIP/PostalCode

San Mateo CALIFORNIA 94402

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

Seidenberg Beth

Street Address 1 Street Address 2

Sagimet Biosciences Inc. 155 Bovet Rd., Unit 303

City State/Province/Country ZIP/PostalCode

San Mateo CALIFORNIA 94402

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

Ringold Gordon

Street Address 1 Street Address 2

Sagimet Biosciences Inc. 155 Bovet Rd., Unit 303

City State/Province/Country ZIP/PostalCode

San Mateo CALIFORNIA 94402

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

Fuller Jason

Street Address 1 Street Address 2

Sagimet Biosciences Inc. 155 Bovet Rd., Unit 303

City State/Province/Country ZIP/PostalCode

San Mateo CALIFORNIA 94402

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

Young James

Street Address 1 Street Address 2

Sagimet Biosciences Inc. 155 Bovet Rd., Unit 303

City State/Province/Country ZIP/PostalCode

San Mateo CALIFORNIA 94402

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

Rodgers Richard

Street Address 1 Street Address 2

Sagimet Biosciences Inc. 155 Bovet Rd., Unit 303

City State/Province/Country ZIP/PostalCode

San Mateo CALIFORNIA 94402

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

Wu Jinzi Jason

Street Address 1 Street Address 2

Sagimet Biosciences Inc. 155 Bovet Rd., Unit 303

City State/Province/Country ZIP/PostalCode

San Mateo CALIFORNIA 94402

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

4. Industry Group

Agriculture Health Care Retailing
Banking & Financial Services X Biotechnology Restaurants

Commercial Banking
Insurance
Health Insurance
Technology
Hospitals & Physicians
Computers

Investing
Investment Banking
Pharmaceuticals
Pooled Investment Fund
Other Health Care
Other Technology

Is the issuer registered as Manufacturing Travel

an investment company under the Investment Company

Real Estate Airlines & Airports

Commercial Lodging & Conventions

No Construction Tourism & Travel Services

Other Banking & Financial Services REITS & Finance Other Travel

Business Services Residential Other

Energy Other Real Estate

Oil & Gas

Coal Mining
Electric Utilities

Energy Conservation
Environmental Services

Act of 1940?

Yes

Other Energy

5. Issuer Size

Revenue Range OR Aggregate Net Asset Value Range

No Revenues No Aggregate Net Asset Value

\$1 - \$1,000,000 \$1 - \$5,000,000

\$1,000,001 - \$5,000,000 \$5,000,001 - \$25,000,000 \$5,000,001 - \$25,000,000 \$25,000,000

\$25,000,001 -\$100,000,000 \$50,000,001 - \$100,000,000

Over \$100,000,000

X Decline to Disclose
Not Applicable

Over \$100,000,000

Decline to Disclose
Not Applicable

6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

Rule 504(b)(1) (not (i), (ii) or (iii))

Investment Company Act Section 3(c)

Rule 504 (b)(1)(i)	Section 3(c)(1)	Section 3(c)(9)
Rule 504 (b)(1)(ii)	Section 3(c)(2)	Section 3(c)(10)
Rule 504 (b)(1)(iii) X Rule 506(b) Rule 506(c) Securities Act Section 4(a)(5)	Section 3(c)(3)	Section 3(c)(11)
	Section 3(c)(4)	Section 3(c)(12)
	Section 3(c)(5)	Section 3(c)(13)
	Section 3(c)(6)	Section 3(c)(14)
	Section 3(c)(7)	

7. Type of Filing

X New Notice Date of First Sale 2020-12-21 First Sale Yet to Occur Amendment

8. Duration of Offering

Does the Issuer intend this offering to last more than one year? Yes X No

9. Type(s) of Securities Offered (select all that apply)

X Equity
Debt
Option, Warrant or Other Right to Acquire Another Security
Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security
Other Right to Acquire Security

Pooled Investment Fund Interests
Tenant-in-Common Securities
Mineral Property Securities
Other (describe)

10. Business Combination Transaction

Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?

Yes X No

Clarification of Response (if Necessary):

11. Minimum Investment

Minimum investment accepted from any outside investor \$0 USD

12. Sales Compensation

Recipient Recipient CRD Number X None

(Associated) Broker or Dealer X None

(Associated) Broker or Dealer CRD
Number

X None

Street Address 1 Street Address 2

City State/Province/Country ZIP/Postal Code

State(s) of Solicitation (select all that apply)
Check "All States" or check individual
States

All
States

Foreign/non-US

13. Offering and Sales Amounts

Total Offering Amount \$80,019,999 USD or Indefinite

Total Amount Sold \$69,019,999 USD

Total Remaining to be Sold \$11,000,000 USD or Indefinite

Clarification of Response (if Necessary):

14. Investors

Select if securities in the offering have been or may be sold to persons who do not qualify as accredited

investors, and enter the number of such non-accredited investors who already have invested in the offering. Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:

112

15. Sales Commissions & Finder's Fees Expenses

Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions \$0 USD Estimate Finders' Fees \$0 USD Estimate

Clarification of Response (if Necessary):

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

\$0 USD Estimate

Clarification of Response (if Necessary):

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Sagimet Biosciences Inc.	/s/Dennis Hom	Dennis Hom	Chief Financial Officer	2020-12-31

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials

under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.					